Best Diffuse Large B Cell Lymphoma Podcasts (2025)

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

12d ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed ... 20:59

25d ago20:59

20:59

In this week's episode we’ll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refract…

1
Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances 59:14

11h ago59:14

59:14

Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. CME information and select publications here.…

1
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature 18:12

4d ago18:12

18:12

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffu…

1
Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies 1:56:57

7d ago1:56:57

1:56:57

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. CME informa…

1
No Scientific Link Found Between Sickle Cell Trait and Sudden Death 21:07

7d ago21:07

21:07

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Excellenc…

1
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell ... 19:06

11d ago19:06

19:06

In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients wit…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

12d ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies 40:11

13d ago40:11

40:11

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME informati…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

14d ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

14d ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2 58:21

17d ago58:21

58:21

Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.By Dr. Neil Love

1
How I Treat Myeloproliferative Neoplasms 38:36

16d ago38:36

38:36

In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions of these authors to How I Treat Myeloproliferative Neoplasms, and exciting advances in the treatment and management of MPNs. See the full How I Treat se…

1
The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL 18:49

18d ago18:49

18:49

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options…

1
Trends in Oncology & Treatment Planning: A Guide to Getting the Best Care 56:59

19d ago56:59

56:59

- Understanding Your Cancer Diagnosis & Treatment Options- Clinical Trial Opportunities: How Research Increases Treatment Options- Factors That May Affect Treatment Planning- How Your Health Care Team May Help You Address Your Care- Participating in Decisions about Your Treatment Plans, Side Effect Prevention & Management- Understanding the Role of…

1
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting 43:18

21d ago43:18

43:18

Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.By Dr. Neil Love

1
Chronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology Summit 50:12

23d ago50:12

50:12

Clinical investigators discuss available data guiding the management of chronic lymphocytic leukemia.  CME information and select publications here.By Dr. Neil Love

1
Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent Conferences 58:13

1M ago58:13

58:13

Dr Catherine C Coombs from UCI Health in Orange County, California, discusses patient cases from her practice and provides an overview of existing and emerging treatment approaches for chronic lymphocytic leukemia. CME information and select publications here.By Research To Practice

1
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL 15:26

1M ago15:26

15:26

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, …

1
Blood Bonus Episode: What is a Blood group? 14:59

1M ago14:59

14:59

In this bonus episode of the Blood podcast, we'll hear from Dr. Nicole Thornton, senior author of the article “Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype”, speaks with Blood Associate Editor Dr. Erica Wood about the discovery of the genetic basis for the inherited AnWj-ne…

1
Does This Star ‘GLO’? Taking Aim at Second-Line Diffuse Large B-Cell Lymphoma With Glofitamab Plus Gemcitabine and Oxaliplatin 20:16

1M ago20:16

20:16

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and an associate professor of medicine at Harvard …

1
Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle ... 19:16

1M ago19:16

19:16

In this week's episode, we’ll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles: Itacitinib…

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

1M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
Updates on CAR T-cell Therapies 53:09

1M ago53:09

53:09

- Overview of CAR T-Cell Therapies- Understanding CARs – Chimeric Antigen Receptors- When to Consider CAR T-Cell Therapies as a Treatment Choice- Clinical Trials for CAR T-Cell Therapies- Discussion of CAR T-Cell Therapies- Managing Potential Treatment Side Effects- Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care- Key Ques…

1
Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards for Oncology Nurses 1:05:16

1M ago1:05:16

1:05:16

Dr Tiffany Richards from The University of Texas MD Anderson Cancer Center in Houston discusses the current and emerging role of bispecific antibodies in the treatment of multiple myeloma. NCPD information and select publications here.By Research To Practice

1
Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis 19:07

2M ago19:07

19:07

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome…

1
Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1 1:05:59

2M ago1:05:59

1:05:59

Ms Robin Klebig from the Mayo Clinic in Rochester, Minnesota, discusses the emerging role of bispecific antibodies in the treatment of non-Hodgkin lymphoma. NCPD information and select publications here.By Dr. Neil Love

1
Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL 21:28

2M ago21:28

21:28

In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL. Featu…

1
Coping with Cancer 1:01:42

2M ago1:01:42

1:01:42

- How to Cope While Waiting for Test Results from Cancer Work-Up- Managing Cancer When You Have Other Health Problems- The Impact of Chronic Illness on Cancer Treatment- The Importance of Adherence: Taking Your Treatment on Schedule- Reducing Harmful Drug Interactions- The Role of Clinical Trials: How Research Increases Your Treatment Options- Know…

1
All Hands on Deck: Spotlight on Clinical Advances in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 51:06

2M ago51:06

51:06

In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and mitigate the impact of AEs associated with novel therapies used in the treatment of patients…

1
Understanding the Different Names for Biomarker Testing and Their Role in Selecting the Best Treatment for You 56:49

2M ago56:49

56:49

- Overview of the Different Names for Biomarker Testing & Why They Can Be Helpful for Treatment- Tumor Marker Testing, Genomic Profiling, Genomic Sequencing, Molecular Profiling, Next Generation Sequencing- The Relationship Between Biomarker Testing & Precision Medicine- Types of Biomarker Tests for Cancer Treatment- Do I Need Biomarker Testing for…

1
Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk 17:48

2M ago17:48

17:48

In this week's podcast, a potential new therapeutic target in beta-thalassemia. The E3 ubiquitin ligase AMBRA1 promotes autophagic clearance of free alpha-globin. Researchers describe mutations in the AMBRA1 gene that impair this clearance, exacerbating ineffective erythropoiesis and disease severity. After that: targeting MYD88 mutations. Lasaloci…

1
Understanding the Important Role that Biomarker Testing Plays in Informing the Treatment of Cancer 58:17

2M ago58:17

58:17

- Overview & Definition of Biomarkers- What are Some Examples of Biomarker Testing- How Biomarker Testing Provides Useful Information for Cancer Treatment- Why the Molecular Portrait of Cancer is so Important- The Role of the Pathologist- Benefits of Biomarker Testing & Precision Medicine- Predicting Response to Treatment- Clinical Trials: How Rese…

1
Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal ... 19:28

2M ago19:28

19:28

In this week's episode we’ll learn more about the significance of hypercalcemia in monoclonal gammopathy of undetermined significance, the role of neutrophil gelatinase-associated lipocalin in hemostasis, and the feasibility of combining CD19-targeted NK- or T-cell therapy with anti-CD19 monoclonal antibodies. Featured Articles: Approaching Hyperca…

1
Review Series on a Quarter Century of TKIs in CML 33:05

2M ago33:05

33:05

In this Review Series episode Reflections on a Quarter Century of TKIs in CML introduced by Associate Editor Dr. Jason Gottlieb, we’ll hear from contributing authors Drs. Brian Drucker, Francois Guillot, Tim Hughes and Michael Deininger, as they discuss how CML treatment has been impacted since the introduction of tyrosine kinase inhibitors 25 year…

1
The Rise of the HLA-Mismatched Unrelated Donor Transplant in the U.S. 26:16

2M ago26:16

26:16

In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine at Stanford University where she focuses on cellular therapy for adults with acute leukemia, talks with Steven Devine, MD, the chief medical officer at the National Marrow Donor Program. They talk about the rise of HLA-mismatched unrelated donor transplants…

1
Advancements in the Management of Relapsed/Refractory B-Cell Malignancies – Integrating Recent Data into Practice to Improve Outcomes 51:52

2M ago51:52

51:52

In this CE Concepts Grand Rounds podcast, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing treatment for patients with R/R MCL, and prioritization of patient adherence and active engagement through de…

1
Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies 2:33:01

2M ago2:33:01

2:33:01

Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making fo…

1
A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes 19:09

2M ago19:09

19:09

In this week's episode, we'll hear about a “belt and suspenders” approach to paroxysmal nocturnal hemoglobinuria, or PNH. We’ll review long-term efficacy data for danicopan—an oral complement factor D inhibitor recently approved as an add-on to C5 inhibitor therapy. After that: researchers show how oral pathogens may exacerbate chronic graft-versus…

1
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer 45:08

2M ago45:08

45:08

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical p…

1
Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy 46:45

3M ago46:45

46:45

Dr Surbhi Sidana from Stanford University in California discusses recent updates on chimeric antigen receptor T-cell therapy for the treatment of multiple myeloma. CME information and select publications here.By Research To Practice

1
Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells 23:14

3M ago23:14

23:14

In this week's episode we’ll find out about longer term results from a pivotal trial of mosunetuzumab in relapsed/refractory follicular lymphoma, potential use of CD70 CAR T-cells that secrete an anti-CD33/anti-CD3 bispecific antibody as a therapy for acute myeloid leukemia, and how ferroptosis regulates hemolysis in stored red blood cells. Feature…

1
Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor 31:38

3M ago31:38

31:38

In this Review Series episode on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor introduced by Dr. Thomas Ortel, we’ll hear from contributing authors Drs. Ben Samuelson Jones, Mac Monroe and Peter Lenting as they discuss how the functional roles of these 3 proteins are interconnected. Click here to view the complete…

1
Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani 46:45

3M ago46:45

46:45

Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York discusses available data guiding treatment decision-making for patients with newly diagnosed multiple myeloma. CME information and select publications here.By Research To Practice

1
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting 20:01

3M ago20:01

20:01

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including: Early results with teclistamab combined with anti-CD38 therapy Real-world data with teclistamab including its use aft…

1
Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor 18:41

3M ago18:41

18:41

In this week's episode we'll learn about asciminib plus dasatinib in Philadelphia chromosome-positive acute leukemia. In a phase 1 study, combining two tyrosine kinase inhibitors with distinct mechanisms of action had encouraging activity in patients with de novo disease. After that: new research demonstrates that the iron exporter ferroportin cont…

1
Clinical Trials: How They Transform the Treatment of Cancer 55:49

3M ago55:49

55:49

- Overview of Clinical Trials & Why They are Important- Understanding Your Treatment Options, Including Clinical Trials- Concerns About Participating in Clinical Trials- Types of Clinical Trials- What Happens in a Clinical Trial?- The Meaning of Informed Consent- Benefits & Risks of Participation- How & Where Clinical Trials are Conducted- How to P…

1
S2 Ep28: Oncology PER® Spectives™: Oncology Consultations®: Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases 29:33

3M ago29:33

29:33

By PER® Spectives

1
The End of Transplant for Mantle Cell Lymphoma 23:29

3M ago23:29

23:29

In this episode, Contributing Editor Brian Hill, MD, PhD, director of the lymphoid malignancies program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, talks with Tim Fenske, MD, who at the time of this recording was joining the transplant and cell therapy group at Sarah Cannon Methodist Healthcare in San Antonio, Texas. Dr. Fe…

1
Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series 59:28

3M ago59:28

59:28

Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center in Columbus reviews existing and emerging treatment strategies for chronic lymphocytic leukemia. CME information and select publications hereBy Research To Practice

Podcasts Worth a Listen

Diffuse Large B Cell Lymphoma Podcasts

Podcasts Worth a Listen

Quick Reference Guide